Galderma Group AG/ADR (GALDY) Stock
GALDY has an Alpha Score of 32 out of 100 (poor), computed on Aug 29, 2026 from 1 of 4 sub-scores. Its trailing P/E ratio is 57.1 and its net margin 14.5% (key statistics as of Oct 21, 2026).
What is GALDY's Alpha Score?
How it works →Alpha Score of 32 reflects weak overall profile with moderate momentum. Based on 1 of 4 signals – score is capped at 50 until remaining data ingests.
Computed from 1 of 4 sub-scores; a sub-score is left out when its inputs are missing, and the composite is capped accordingly.
Computed Aug 29, 2026 · 54 days ago; due for a rescore
A rules-based research rating, not a recommendation to buy or sell.
What are GALDY's key statistics?
Key statistics as of Oct 21, 2026
How does GALDY's valuation compare with the Healthcare sector?
| Metric | GALDY | Healthcare median | Companies in median |
|---|---|---|---|
| P/E ratio | 57.1 | 27.0 | 75 |
| Net margin | 14.54% | 9.40% | 92 |
| Return on equity | 7.71% | 11.24% | 99 |
Medians over the Healthcare stocks whose key statistics were refreshed in the last 35 days (newest Oct 22, 2026). P/E excludes loss-making companies.
GALDY price chart
Powered by TradingViewWhat does Galderma Group AG/ADR do?
Galderma Group AG Unsponsored ADR represents a special equity instrument, allowing United States investors to invest in this Switzerland-based dermatology company without trading directly on foreign exchanges. As an unsponsored American Depositary Receipt, it is issued by a depositary bank, allowing the ADR to be traded on U.S. markets. This instrument facilitates access to Galderma Group AG, a company known for its specialized focus on skincare, dermatological products, and professional health solutions. Offering a diverse range of products covering aesthetic treatments, skin health services, and prescription dermatology products, Galderma significantly impacts sectors related to healthcare and personal care. Its position in the dermatology field underscores the role of this ADR in diversifying portfolios, particularly for those interested in healthcare innovations and the growing demand for skin treatments. The Galderma ADR illustrates the accessibility and convenience provided by ADRs in making foreign investments more palatable for American investors who prefer trading in USD and within their local financial systems.